Michael A. Shirley

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

Keith Dredge, Rebecca Horsfall, Simon P. Robinson et al. · Microvascular Research · 2005 · 268 citations

Medicine, Oncology, Pharmacology +13

Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.

Marco M. Gottardis, Eric D. Bischoff, Michael A. Shirley et al. · PubMed · 1996 · 201 citations

Medicine, Oncology, Pharmacology +17

Discovery of (<i>S</i>)-<i>N</i>-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1<i>H</i>-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

Hon‐Wah Man, Peter Schäfer, Lu Min Wong et al. · Journal of Medicinal Chemistry · 2009 · 182 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor

Véronique Plantevin Krenitsky, Lisa Nadolny, Mercedes Delgado et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 114 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

The Synthetic Compound CC-5079 Is a Potent Inhibitor of Tubulin Polymerization and Tumor Necrosis Factor-α Production with Antitumor Activity

Linghua Zhang, Lei Wu, Heather K. Raymon et al. · Cancer Research · 2006 · 91 citations

Medicine, Oncology, Pharmacology +14